203 related articles for article (PubMed ID: 23001705)
1. Biomarkers of parathyroid carcinoma.
Erovic BM; Harris L; Jamali M; Goldstein DP; Irish JC; Asa SL; Mete O
Endocr Pathol; 2012 Dec; 23(4):221-31. PubMed ID: 23001705
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive markers in medullary thyroid carcinoma.
Erovic BM; Kim D; Cassol C; Goldstein DP; Irish JC; Asa SL; Mete O
Endocr Pathol; 2012 Dec; 23(4):232-42. PubMed ID: 23150029
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel target proteins in sebaceous gland carcinoma.
Erovic BM; Al Habeeb A; Harris L; Goldstein DP; Kim D; Ghazarian D; Irish JC
Head Neck; 2013 May; 35(5):642-8. PubMed ID: 22715107
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis.
Stojadinovic A; Hoos A; Nissan A; Dudas ME; Cordon-Cardo C; Shaha AR; Brennan MF; Singh B; Ghossein RA
Hum Pathol; 2003 Jan; 34(1):54-64. PubMed ID: 12605367
[TBL] [Abstract][Full Text] [Related]
5. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
[TBL] [Abstract][Full Text] [Related]
6. VEGFR-2 is downregulated in sestamibi-negative parathyroid adenomas.
Erovic BM; Goldstein DP; Asa SL; Janik S; Mete O; Irish JC
Head Neck; 2019 Oct; 41(10):3564-3569. PubMed ID: 31291025
[TBL] [Abstract][Full Text] [Related]
7. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
[TBL] [Abstract][Full Text] [Related]
8. Defining a molecular phenotype for benign and malignant parathyroid tumors.
Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas.
Juhlin CC; Haglund F; Villablanca A; Forsberg L; Sandelin K; Bränström R; Larsson C; Höög A
Int J Oncol; 2009 Feb; 34(2):481-92. PubMed ID: 19148484
[TBL] [Abstract][Full Text] [Related]
10. Filamin A and parafibromin expression in parathyroid carcinoma.
Storvall S; Leijon H; Ryhänen EM; Vesterinen T; Heiskanen I; Schalin-Jäntti C; Arola J
Eur J Endocrinol; 2021 Oct; 185(6):803-812. PubMed ID: 34606470
[TBL] [Abstract][Full Text] [Related]
11. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
[TBL] [Abstract][Full Text] [Related]
12. Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.
Silva-Figueroa AM; Bassett R; Christakis I; Moreno P; Clarke CN; Busaidy NL; Grubbs EG; Lee JE; Perrier ND; Williams MD
Endocr Pathol; 2019 Dec; 30(4):285-296. PubMed ID: 31734935
[TBL] [Abstract][Full Text] [Related]
13. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma.
Árvai K; Nagy K; Barti-Juhász H; Peták I; Krenács T; Micsik T; Végső G; Perner F; Szende B
Pathol Oncol Res; 2012 Jul; 18(3):607-14. PubMed ID: 22198862
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
16. Impact of Sonic Hedgehog Pathway Expression on Outcome in HPV Negative Head and Neck Carcinoma Patients after Surgery and Adjuvant Radiotherapy.
Enzenhofer E; Parzefall T; Haymerle G; Schneider S; Kadletz L; Heiduschka G; Pammer J; Oberndorfer F; Wrba F; Loader B; Grasl MC; Perisanidis C; Erovic BM
PLoS One; 2016; 11(12):e0167665. PubMed ID: 27918595
[TBL] [Abstract][Full Text] [Related]
17. High expression of Sonic hedgehog signaling proteins is related to the favorable outcome, EGFR mutation, and lepidic predominant subtype in primary lung adenocarcinoma.
Kim JE; Kim H; Choe JY; Sun P; Jheon S; Chung JH
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S570-6. PubMed ID: 23709101
[TBL] [Abstract][Full Text] [Related]
18. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues.
Naccarato AG; Marcocci C; Miccoli P; Bonadio AG; Cianferotti L; Vignali E; Cipollini G; Viacava P
J Endocrinol Invest; 1998 Mar; 21(3):136-41. PubMed ID: 9591207
[TBL] [Abstract][Full Text] [Related]
20. Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas.
Zheng HC; Takahashi H; Li XH; Hara T; Masuda S; Guan YF; Takano Y
Virchows Arch; 2008 Feb; 452(2):147-55. PubMed ID: 18080135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
